Vedolizumab

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Moens (Controls exposed to TNFi), 2020	Europe 2009 - 2018	Pregnant women with inflammatory bowel diseases (IBD) treated or not.	Pregnancies exposed to Vedolizumab.	exposed to other treatment, sick Pregnancies exposed to anti‐TNF.	79 / 186	Three (4%) women initiated VDZ treatment after conception.
Moens (Controls unexposed, sick), 2020	Europe 2009 - 2018	Pregnant women with inflammatory bowel diseases (IBD) treated or not.	Pregnancies exposed to Vedolizumab.	unexposed, sick Pregnancies that were not exposed to biologics nor to immunomodulatory drugs.	79 / 184	Three (4%) women initiated VDZ treatment after conception.

Study	Country Study period	Case	Control	Sample size	Rmk

5 studies, not fulfilled eligibility criteria, were excluded. See excluded tab for the list of these studies and reason of exclusion.